References
- Denning DW. Echinocandins: a new class of antifungal. J Antimicrob Chemother 2002;49:889–91.
- Sable CA, Nguyen BYT, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002;4:25–30.
- Raasch RH. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev Anti Infect Ther 2004;2: 499–508.
- Groll AH, Stergiopoulou T, Roilides E, Walsh TJ. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs 2005;14:489–509.
- Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol 2010;126:39–44.
- Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563–71.
- Kargili A, Bavbek N, Kaya A, Kosar A, Karaaslan Y. Eosinophilia in rheumatologic diseases: a prospective study of 1000 cases. Rheumatol Int 2004;24:321–4.
- Darmanata JI, van Zandwijk N, Düren DR, van Royen EA, Mooi WJ, Plomp TA, et al. Amiodarone pneumonitis: three further cases with a review of published reports. Thorax 1984;39:57–64.
- Allen JN, Davis WB. Eosinophilic lung diseases. Am J Respir Crit Care Med 1994;150:1423–38.
- Allen JN. Drug-induced eosinophilic lung disease. Clin Chest Med 2004;25:77–88.